Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study.
van der Kooij MK, Dekkers OM, Aarts MJB, van den Berkmortel FWPJ, Boers-Sonderen MJ, de Groot JWB, Hospers GAP, Piersma D, van Rijn RS, Suijkerbuijk KPM, Westgeest HM, van der Veldt AAM, Vreugdenhil G, Wilgenhof S, Wouters MWJM, Haanen JBAG, van den Eertwegh AJM, Kapiteijn E. van der Kooij MK, et al. Among authors: wilgenhof s. Cancers (Basel). 2021 Sep 16;13(18):4639. doi: 10.3390/cancers13184639. Cancers (Basel). 2021. PMID: 34572865 Free PMC article.
Adoptive cellular therapies: the current landscape.
Rohaan MW, Wilgenhof S, Haanen JBAG. Rohaan MW, et al. Among authors: wilgenhof s. Virchows Arch. 2019 Apr;474(4):449-461. doi: 10.1007/s00428-018-2484-0. Epub 2018 Nov 23. Virchows Arch. 2019. PMID: 30470934 Free PMC article. Review.
Cytomegalovirus in Steroid-Refractory Immune Checkpoint Inhibition-Related Colitis.
van Turenhout ST, Berghuis M, Snaebjornsson P, Wilgenhof S, Burgers JA, Haanen JBAG, van Dieren JM. van Turenhout ST, et al. Among authors: wilgenhof s. J Thorac Oncol. 2020 Jan;15(1):e15-e20. doi: 10.1016/j.jtho.2019.07.026. J Thorac Oncol. 2020. PMID: 31864555 Free article. No abstract available.
Neoadjuvant Cytoreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR: A Prospective, Single-arm, Open-label Phase II Trial.
Blankenstein SA, Rohaan MW, Klop WMC, van der Hiel B, van de Wiel BA, Lahaye MJ, Adriaansz S, Sikorska K, van Tinteren H, Sari A, Grijpink-Ongering LG, van Houdt WJ, Wouters MWJM, Blank CU, Wilgenhof S, van Thienen JV, van Akkooi ACJ, Haanen JBAG. Blankenstein SA, et al. Among authors: wilgenhof s. Ann Surg. 2021 Aug 1;274(2):383-389. doi: 10.1097/SLA.0000000000004893. Ann Surg. 2021. PMID: 33843797 Clinical Trial.
Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment.
Meerveld-Eggink A, Graafland N, Wilgenhof S, Van Thienen JV, Lalezari F, Grant M, Szabados B, Abu-Ghanem Y, Kuusk T, Boleti E, Blank CU, Haanen JBAG, Powles T, Bex A. Meerveld-Eggink A, et al. Among authors: wilgenhof s. Eur Urol Open Sci. 2022 Jan 3;35:54-58. doi: 10.1016/j.euros.2021.11.003. eCollection 2022 Jan. Eur Urol Open Sci. 2022. PMID: 35024632 Free PMC article.
MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial.
Rohaan MW, Gomez-Eerland R, van den Berg JH, Geukes Foppen MH, van Zon M, Raud B, Jedema I, Scheij S, de Boer R, Bakker NAM, van den Broek D, Pronk LM, Grijpink-Ongering LG, Sari A, Kessels R, van den Haak M, Mallo HA, Karger M, van de Wiel BA, Zuur CL, Duinkerken CW, Lalezari F, van Thienen JV, Wilgenhof S, Blank CU, Beijnen JH, Nuijen B, Schumacher TN, Haanen JBAG. Rohaan MW, et al. Among authors: wilgenhof s. Immunooncol Technol. 2022 Jun 18;15:100089. doi: 10.1016/j.iotech.2022.100089. eCollection 2022 Sep. Immunooncol Technol. 2022. PMID: 35865122 Free PMC article.
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.
Rohaan MW, Borch TH, van den Berg JH, Met Ö, Kessels R, Geukes Foppen MH, Stoltenborg Granhøj J, Nuijen B, Nijenhuis C, Jedema I, van Zon M, Scheij S, Beijnen JH, Hansen M, Voermans C, Noringriis IM, Monberg TJ, Holmstroem RB, Wever LDV, van Dijk M, Grijpink-Ongering LG, Valkenet LHM, Torres Acosta A, Karger M, Borgers JSW, Ten Ham RMT, Retèl VP, van Harten WH, Lalezari F, van Tinteren H, van der Veldt AAM, Hospers GAP, Stevense-den Boer MAM, Suijkerbuijk KPM, Aarts MJB, Piersma D, van den Eertwegh AJM, de Groot JB, Vreugdenhil G, Kapiteijn E, Boers-Sonderen MJ, Fiets WE, van den Berkmortel FWPJ, Ellebaek E, Hölmich LR, van Akkooi ACJ, van Houdt WJ, Wouters MWJM, van Thienen JV, Blank CU, Meerveld-Eggink A, Klobuch S, Wilgenhof S, Schumacher TN, Donia M, Svane IM, Haanen JBAG. Rohaan MW, et al. Among authors: wilgenhof s. N Engl J Med. 2022 Dec 8;387(23):2113-2125. doi: 10.1056/NEJMoa2210233. N Engl J Med. 2022. PMID: 36477031 Clinical Trial.
55 results